{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:31:27Z","timestamp":1787027487087,"version":"build-2736575974"},"reference-count":47,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Prolonged broad-spectrum antibiotic use is more likely to induce bacterial resistance and dysbiosis of skin and gut microflora. First and second-generation tetracycline-class antibiotics have similar broad-spectrum antibacterial activity. Targeted tetracycline-class antibiotics are needed to limit antimicrobial resistance and improve patient outcomes. Sarecycline is a narrow-spectrum, third-generation tetracycline-class antibiotic Food and Drug Administration (FDA)-approved for treating moderate-to-severe acne. In vitro studies demonstrated activity against clinically relevant Gram-positive bacteria but reduced activity against Gram-negative bacteria. Recent studies have provided insight into how the structure of sarecycline, with a unique C7 moiety, interacts with bacterial ribosomes to block translation and prevent antibiotic resistance. Sarecycline reduces Staphylococcus aureus DNA and protein synthesis with limited effects on RNA, lipid, and bacterial wall synthesis. In agreement with in vitro data, sarecycline demonstrated narrower-spectrum in vivo activity in murine models of infection, exhibiting activity against S. aureus, but reduced efficacy against Escherichia coli compared to doxycycline and minocycline. In a murine neutropenic thigh wound infection model, sarecycline was as effective as doxycycline against S. aureus. The anti-inflammatory activity of sarecycline was comparable to doxycycline and minocycline in a rat paw edema model. Here, we review the antibacterial mechanisms of sarecycline and report results of in vivo studies of infection and inflammation.<\/jats:p>","DOI":"10.3390\/antibiotics10040439","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T12:11:00Z","timestamp":1618488660000},"page":"439","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4011-8308","authenticated-orcid":false,"given":"Christopher G.","family":"Bunick","sequence":"first","affiliation":[{"name":"Department of Dermatology, Yale University School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonette","family":"Keri","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33128, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Ken","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Paratek Pharma, Boston, MA 02109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nika","family":"Furey","sequence":"additional","affiliation":[{"name":"R&amp;D and Medical Affairs, Almirall US, Exton, PA 19341, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2390-6505","authenticated-orcid":false,"given":"Giovanni","family":"Damiani","sequence":"additional","affiliation":[{"name":"Clinical Dermatology, IRCCS Galeazzi Orthopaedic Institute, Via Riccardo Galeazzi, 4, 20161 Milan, Italy"},{"name":"Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20121 Milan, Italy"},{"name":"Department of Pharmaceutical and Pharmacological Sciences, University of Padua, 35139 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8328-5587","authenticated-orcid":false,"given":"Jodi L.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Departments of Pathology &amp; Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5321-0584","authenticated-orcid":false,"given":"Ayman","family":"Grada","sequence":"additional","affiliation":[{"name":"R&amp;D and Medical Affairs, Almirall US, Exton, PA 19341, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/dth.12370","article-title":"The use of oral antibiotics in treating acne vulgaris: A new approach","volume":"29","author":"Farrah","year":"2016","journal-title":"Dermatol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/jamadermatol.2018.4944","article-title":"Trends in Oral Antibiotic Prescription in Dermatology, 2008 to 2016","volume":"155","author":"Barbieri","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_3","first-page":"18","article-title":"Status Report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 1: Antibiotic Prescribing Patterns, Sources of Antibiotic Exposure, Antibiotic Consumption and Emergence of Antibiotic Resistance, Impact of Alterations in Antibiotic Prescribing, and Clinical Sequelae of Antibiotic Use","volume":"9","author":"Webster","year":"2016","journal-title":"J. Clin. Aesthetic Dermatol."},{"key":"ref_4","unstructured":"Talkington, K. (2020, November 08). The U.S. Is Not Prepared to Combat \u2018Existential Threat\u2019 of Antibiotic-Resistant Superbugs. PEW Charitable Trusts. Available online: https:\/\/www.pewtrusts.org\/en\/research-and-analysis\/articles\/2020\/07\/27\/the-us-is-not-prepared-to-combat-existential-threat-of-antibiotic-resistant-superbugs."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1021\/acs.chemrev.0c01214","article-title":"The Antibiotic Resistome: A Guide for the Discovery of Natural Products as Antimicrobial Agents","volume":"121","author":"Hobson","year":"2021","journal-title":"Chem. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.3389\/fmicb.2015.01543","article-title":"Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances","volume":"6","author":"Francino","year":"2016","journal-title":"Front. Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1128\/AAC.7.1.55","article-title":"Comparative Effect of Tetracycline and Doxycycline on the Occurrence of Resistant Escherichia coli in the Fecal Flora","volume":"7","author":"Bartlett","year":"1975","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Alkhawaja, E., Hammadi, S., Abdelmalek, M., Mahasneh, N., Alkhawaja, B., and Abdelmalek, S.M. (2020). Antibiotic resistant Cutibacterium acnes among acne patients in Jordan: A cross sectional study. BMC Dermatol., 20.","DOI":"10.1186\/s12895-020-00108-9"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"adv00295","DOI":"10.2340\/00015555-3654","article-title":"Antibiotic Susceptibility of Cutibacterium acnes Strains Isolated from Israeli Acne Patients","volume":"100","author":"Rimon","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2133.2004.05749.x","article-title":"Inflammation in acne scarring: A comparison of the responses in lesions from patients prone and not prone to scar","volume":"150","author":"Holland","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"ref_11","first-page":"1407","article-title":"Doxycycline and minocycline for the management of acne: A review of efficacy and safety with emphasis on clinical implications","volume":"9","author":"Kircik","year":"2010","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5021\/ad.2020.32.1.21","article-title":"Minocycline and Its Impact on Microbial Dysbiosis in the Skin and Gastrointestinal Tract of Acne Patients","volume":"32","author":"Thompson","year":"2020","journal-title":"Ann. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/imj.12179","article-title":"Association of doxycycline use with the development of gastroenteritis, irritable bowel syndrome and inflammatory bowel disease in Australians deployed abroad","volume":"43","author":"Lee","year":"2013","journal-title":"Intern. Med. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1038\/ajg.2010.303","article-title":"Potential Association Between the Oral Tetracycline Class of Antimicrobials Used to Treat Acne and Inflammatory Bowel Disease","volume":"105","author":"Margolis","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S2468-1253(20)30267-3","article-title":"Antibiotic use and the development of inflammatory bowel disease: A national case-control study in Sweden","volume":"5","author":"Nguyen","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_16","first-page":"s6","article-title":"Oral Tetracyclines and Acne: A Systematic Review for Dermatologists","volume":"19","author":"Armstrong","year":"2020","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1128\/AAC.05947-11","article-title":"Antibiotic Exposure as a Risk Factor for Fluconazole-Resistant Candida Bloodstream Infection","volume":"56","author":"Krieger","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0002-9378(99)70141-9","article-title":"Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis","volume":"180","author":"Spinillo","year":"1999","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1128\/AAC.8.6.713","article-title":"Relation Between Lipophilicity and Pharmacological Behavior of Minocycline, Doxycycline, Tetracycline, and Oxytetracycline in Dogs","volume":"8","author":"Barza","year":"1975","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2133.1996.tb06972.x","article-title":"Safety of long-term high-dose minocycline in the treatment of acne","volume":"134","author":"Goulden","year":"1996","journal-title":"Br. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1091-8531(99)70095-9","article-title":"Pediatric tetracycline-induced pseudotumor cerbri","volume":"3","author":"Quinn","year":"1999","journal-title":"J. AAPOS"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/infdis\/jix211","article-title":"White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs","volume":"216","author":"Boucher","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_23","unstructured":"Administration UFaD (2021, March 06). Drug Approval Package: Seysara (sarecycline). US Department of Health and Human Services, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/209521Orig1s000TOC.cfm."},{"key":"ref_24","unstructured":"Almirall (2020). SEYSARA\u2122 (Sarecycline) Tablets for Oral Use, Almirall, LLC."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2147\/CCID.S190473","article-title":"Sarecycline: A Review of Preclinical and Clinical Evidence","volume":"13","author":"Moore","year":"2020","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20530","DOI":"10.1073\/pnas.2008671117","article-title":"Sarecycline interferes with tRNA accommodation and tethers mRNA to the 70S ribosome","volume":"117","author":"Batool","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","article-title":"Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance","volume":"65","author":"Chopra","year":"2001","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.jid.2020.03.586","article-title":"576 Crystal structure of sarecycline bound to the 70S bacterial ribosome reveals structural differences from other tetracyclines at atomic resolution","volume":"140","author":"Batool","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1128\/AAC.00594-16","article-title":"rRNA Binding Sites and the Molecular Mechanism of Action of the Tetracyclines","volume":"60","author":"Chukwudi","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Zhanel, G., Critchley, I., Lin, L.-Y., and Alvandi, N. (2018). Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.01297-18"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1128\/AAC.11.2.318","article-title":"Tetracycline Inhibits Propagation of Deoxyribonucleic Acid Replication and Alters Membrane Properties","volume":"11","author":"Pato","year":"1977","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"573","DOI":"10.4103\/1947-2714.103317","article-title":"Staphylococcus aureus in acne pathogenesis: A case-control study","volume":"4","author":"Abdi","year":"2012","journal-title":"N. Am. J. Med Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1001\/archdermatol.2011.67","article-title":"Antibiotics, Acne, and Staphylococcus aureus Colonization","volume":"147","author":"Fanelli","year":"2011","journal-title":"Arch. Dermatol."},{"key":"ref_34","first-page":"987","article-title":"Once-Daily Oral Sarecycline 1.5 mg\/kg\/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials","volume":"17","author":"Moore","year":"2018","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_35","first-page":"E53","article-title":"Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity Study","volume":"12","author":"Pariser","year":"2019","journal-title":"J. Clin. Aesthetic Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1515\/hsz-2013-0292","article-title":"Tetracycline antibiotics and resistance mechanisms","volume":"395","author":"Nguyen","year":"2014","journal-title":"Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"a025387","DOI":"10.1101\/cshperspect.a025387","article-title":"Tetracycline Antibiotics and Resistance","volume":"6","author":"Grossman","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"16900","DOI":"10.1073\/pnas.1208037109","article-title":"Structural basis for TetM-mediated tetracycline resistance","volume":"109","author":"Franckenberg","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","first-page":"1","article-title":"Mechanism of tetracycline resistance by ribosomal protection protein Tet(O)","volume":"4","author":"Li","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1529-8019.2012.01497.x","article-title":"New antibiotic therapies for acne and rosacea","volume":"25","author":"Mays","year":"2012","journal-title":"Dermatol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/ajd.12075","article-title":"Non-antibiotic properties of tetracyclines and their clinical application in dermatology","volume":"55","author":"Perret","year":"2014","journal-title":"Australas. J. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.phrs.2010.10.004","article-title":"Tetracycline compounds with non-antimicrobial organ protective properties: Possible mechanisms of action","volume":"63","author":"Griffin","year":"2011","journal-title":"Pharmacol. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.det.2007.01.012","article-title":"Anti-Inflammatory Activity of Tetracyclines","volume":"25","author":"Webster","year":"2007","journal-title":"Dermatol. Clin."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4103\/0019-5154.190105","article-title":"Anti-inflammatory and immunomodulatory effects of antibiotics and their use in dermatology","volume":"61","author":"Madke","year":"2016","journal-title":"Indian J. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejphar.2004.10.039","article-title":"Lack of evidence of direct mitochondrial involvement in the neuroprotective effect of minocycline","volume":"505","author":"Cornet","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejphar.2007.07.049","article-title":"Characterization of the antinociceptive and anti-inflammatory activities of doxycycline and minocycline in different experimental models","volume":"576","author":"Bastos","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"ref_47","first-page":"333","article-title":"Efficacy and Safety of Sarecycline, a Novel, Once-Daily, Narrow Spectrum Antibiotic for the Treatment of Moderate to Severe Facial Acne Vulgaris: Results of a Phase 2, Dose-Ranging Study","volume":"17","author":"Leyden","year":"2018","journal-title":"J. Drugs Dermatol. JDD"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/4\/439\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:48:13Z","timestamp":1760161693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/4\/439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["antibiotics10040439"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10040439","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]}}}